Koninklijke Philips (PHIA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
The meeting opened with introductions of the Board, Supervisory Board, and key committee members, emphasizing the importance of the AGM and shareholder engagement.
The agenda included financial performance, dividend policy, board appointments, remuneration, ESG progress, and voting procedures.
Financial performance review
2024 saw solid progress in innovation and profitability, but growth was impacted by deteriorated demand in China and global economic uncertainty.
Profitability and cash flow improved, and the balance sheet was strengthened despite global headwinds.
The company adjusted growth expectations for 2025, prioritizing profitable growth and resilience.
Board and executive committee updates
Several new executive appointments were highlighted, including a new CFO and leaders for China, Precision Diagnosis, and International Region.
Proposals were made to appoint Bob White to the Supervisory Board and reappoint Indra Nooyi, Chua Sock Koong, and Marnix van Ginneken.
David Pyott was thanked for his service as Chair of the Quality and Regulatory Committee.
Latest events from Koninklijke Philips
- Strong margin gains and resilient performance offset flat sales and China demand weakness.PHIA
Q3 20249 Jul 2026 - Margin expansion and higher free cash flow drive improved 2025 outlook despite ongoing risks.PHIA
Q2 20258 Jul 2026 - All AGM proposals passed with strong support amid focus on innovation, governance, and risk.PHIA
AGM 20268 Jul 2026 - Q3 2025 saw 8% order intake growth, 3% sales growth, and margin expansion to 12.3%.PHIA
Q3 20258 Jul 2026 - Targeting mid-single-digit growth and mid-teens margins by 2028 through AI-driven platforms and execution.PHIA
CMD 20261 Jul 2026 - Q1 2026 delivered strong sales and margin growth, with guidance reaffirmed amid global risks.PHIA
Q1 20269 May 2026 - Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026 - AI-driven health innovation and open platforms fuel growth and ESG leadership.PHIA
Show & Tell 202420 Jan 2026